Gain Therapeutics (GANX) Accumulated Depreciation & Amortization (2020 - 2025)
Historic Accumulated Depreciation & Amortization for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $169608.0.
- Gain Therapeutics' Accumulated Depreciation & Amortization rose 3941.38% to $169608.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $169608.0, marking a year-over-year increase of 3941.38%. This contributed to the annual value of $123357.0 for FY2024, which is 3293.21% up from last year.
- According to the latest figures from Q3 2025, Gain Therapeutics' Accumulated Depreciation & Amortization is $169608.0, which was up 3941.38% from $159709.0 recorded in Q2 2025.
- Over the past 5 years, Gain Therapeutics' Accumulated Depreciation & Amortization peaked at $169608.0 during Q3 2025, and registered a low of $3403.0 during Q1 2021.
- Over the past 5 years, Gain Therapeutics' median Accumulated Depreciation & Amortization value was $71933.0 (recorded in 2023), while the average stood at $74819.4.
- As far as peak fluctuations go, Gain Therapeutics' Accumulated Depreciation & Amortization surged by 2705.05% in 2021, and later skyrocketed by 87105.5% in 2022.
- Quarter analysis of 5 years shows Gain Therapeutics' Accumulated Depreciation & Amortization stood at $15484.0 in 2021, then surged by 244.41% to $53329.0 in 2022, then skyrocketed by 74.01% to $92797.0 in 2023, then skyrocketed by 32.93% to $123357.0 in 2024, then skyrocketed by 37.49% to $169608.0 in 2025.
- Its Accumulated Depreciation & Amortization stands at $169608.0 for Q3 2025, versus $159709.0 for Q2 2025 and $136778.0 for Q1 2025.